MHRA Strep A Vaccine Research, World Diabetes Day & Liverpool Medicine Spotlight

New research published this month by MHRA scientists has brought a needle-free vaccine against Group A Streptococcus (Strep A) a significant step closer to reality.

The study, published in Human Vaccines & Immunotherapeutics in partnership with the GSK Vaccines Institute for Global Health, demonstrates promising results for vaccines that could be delivered through the nose or under the tongue rather than by injection. There is currently no licensed vaccine for Strep A, despite it causing hundreds of millions of infections globally and leading to serious complications including long-term disability and death.

The research uses Generalised Modules for Membrane Antigens (GMMA) technology—tiny bubbles naturally shed from bacteria that act as both a carrier for the Strep A carbohydrate antigen and an immune-boosting adjuvant. Unlike conventional vaccines that primarily generate antibodies in the bloodstream, this approach targets immunity at mucosal surfaces in the nose and throat where Strep A establishes infection, while also inducing a broader systemic immune response.

Why this matters for interviews: This story touches multiple high-value themes. First, innovation in vaccine delivery—needle-free administration could improve global access, particularly in low- and middle-income countries where the burden of Strep A is greatest. Second, antimicrobial resistance: by preventing infections before they occur, vaccines reduce antibiotic consumption and support AMR efforts. Third, regulatory science: this is MHRA conducting its own primary research, not just approving products—demonstrating the breadth of roles within medicines regulation.

Dr Fatme Mawas, Head of Conjugate Vaccines at MHRA, noted the approach "could make vaccines easier to administer and more accessible globally."

Work was conducted in pre-clinical (mouse) models and forms part of MHRA's wider programme exploring vaccine science, immunology, and novel delivery technologies. While clinical trials in humans will be the next critical step, the research demonstrates proof-of-concept for mucosal immunisation against a pathogen that has long evaded vaccine development.

Interview angle: If asked about recent advances, structure your answer around the innovation (mucosal delivery), the unmet need (no Strep A vaccine despite global burden), and the wider public-health implications (equity of access, AMR). Avoid overstating readiness—this is pre-clinical research, not an approved product.

World Diabetes Day falls this coming Friday, 14 November, with a 2026 theme of "Early action on diabetes"—highlighting the importance of earlier diagnosis, comprehensive care access, and reducing stigma.

The campaign is grounded in a stark reality: more than 40% of people living with diabetes remain undiagnosed. One of the five global diabetes coverage targets supported by WHO Member States aims for 80% of people with diabetes to be diagnosed by 2030—a target that underscores just how large the gap remains.

The diagnosis challenge

Type 1 diabetes often develops rapidly with clear symptoms, but type 2 diabetes typically develops gradually and may cause few or no noticeable early signs. Common symptoms include increased thirst, frequent urination, tiredness, and blurred vision—but many people attribute these to other causes or simply don't notice them until complications develop.

Type 1 diabetes is frequently missed or misdiagnosed, particularly in adults, where it may not fit the classic paediatric presentation. Recognising symptoms early can lead to life-saving treatment; delayed diagnosis risks diabetic ketoacidosis (DKA), a medical emergency.

Why the gap matters

According to the International Diabetes Federation, an estimated 24.6 million adults aged 20–79 were living with diabetes in the WHO African Region in 2024, projected to reach 59.5 million by 2050. Alarmingly, nearly three out of four adults living with diabetes in this region remain undiagnosed—the highest proportion globally. Many are at risk of serious complications including kidney failure, blindness, cardiovascular disease, and lower-limb amputations.

The interview lens

This day offers rich material for discussing health inequalities (diagnosis gaps disproportionately affect low-resource settings), prevention versus treatment (type 2 diabetes is largely preventable through environmental and lifestyle interventions), and the social determinants of health (access to healthy food, safe spaces for physical activity, and quality health services).

It also raises an ethics question worth rehearsing: if diagnosis only improves outcomes when followed by access to affordable care and ongoing support, where should health systems prioritise investment—screening programmes or treatment infrastructure? Both are necessary, but finite resources force choices. There's no single right answer, but a strong answer will acknowledge trade-offs, cite the principle of justice (equitable access), and consider both individual benefit and population-level impact.

The 2026 campaign calls for integration of diabetes prevention, early detection, and person-centred care into primary health care; expansion of access to affordable insulin and essential medicines; and progress towards the WHO Global Diabetes Compact targets. For applicants, it's a reminder that awareness days are not just symbolic—they're advocacy tools designed to shift policy and funding.

The MHRA Strep A vaccine research featured above offers an opportunity to explore a recurring ethical tension in global health innovation: technologies designed to improve equity can inadvertently widen it.

The promise

Needle-free, mucosal vaccines sound like an obvious win. They eliminate sharps waste, reduce needle-stick injury risk, may improve uptake (particularly among needle-phobic populations), and—critically—simplify the cold chain and delivery logistics that often limit vaccine reach in low-resource settings. The MHRA researchers explicitly frame their work as benefiting low- and middle-income countries where the Strep A disease burden is greatest.

The paradox

But innovation costs money. New vaccine platforms require years of clinical trials, regulatory pathways that may not yet exist, and manufacturing scale-up. Even if a needle-free Strep A vaccine proves safe and effective, will it be affordable where it's needed most? Will intellectual property arrangements permit local production, or will supply be controlled by a handful of manufacturers in high-income countries?

History offers cautionary examples. The pneumococcal conjugate vaccine (PCV) dramatically reduced childhood pneumonia and meningitis—but cost and supply constraints delayed its introduction in many low-income countries for years after wealthy nations rolled it out. Equity in access lagged equity in need.

The discussion

This is a justice question (fair distribution of benefits and burdens) intersecting with beneficence (acting in patients' best interests). A few lines of argument:

Argument for prioritising innovation: Without the breakthrough, there's no vaccine for anyone. Research in high-income settings generates knowledge that eventually diffuses globally. Delaying innovation to wait for guaranteed equitable access means more people suffer in the interim.

Argument for conditional development: Publicly funded research (MHRA is a UK government agency) should come with strings attached—advance purchase commitments for low-income countries, technology transfer agreements, or tiered pricing structures built in from the start. If equity is the stated goal, it must be operationalised, not assumed.

The middle ground: Develop the vaccine, but use existing frameworks (GAVI, COVAX-style mechanisms, WHO prequalification) to ensure equitable access is part of the pathway to licensure, not an afterthought.

For your interview

If this comes up, avoid simplistic answers. Acknowledge the genuine intent behind equity-focused innovation, but recognise that good intentions require robust mechanisms. Reference real-world examples (COVID-19 vaccine inequity, PCV delays) to demonstrate awareness that this is a known, systemic challenge—not a hypothetical risk. Finish with a principle: innovation should be accompanied by plans for equitable distribution, and where public money funds the research, the public (globally) should benefit.

The Strep A vaccine story is a perfect case study for a common interview trap: discussing medical advances that sound revolutionary but remain years from clinical use.

Here's how to avoid overstating findings while still demonstrating genuine engagement.

The trap

"Tell me about a recent medical advance." You mention the MHRA Strep A study. The interviewer probes: "So when will this be available to patients?" If you answer "soon" or "in the next few years," you've misrepresented pre-clinical research. If you say "I don't know," you sound disengaged.

The structure

1. Name the stage clearly: "This was a pre-clinical study in mice, published in October, demonstrating proof-of-concept for a needle-free Strep A vaccine using mucosal delivery."

*2. Explain why it matters now***: "There's currently no licensed Strep A vaccine despite hundreds of millions of infections globally, so any progress toward one is significant. The mucosal delivery approach is particularly interesting because it targets immunity where infection starts—the nose and throat—and could improve access in low-resource settings."

3. Acknowledge what comes next: "The next steps would be safety and efficacy trials in humans, which take years, followed by regulatory approval and manufacturing scale-up. So this is early-stage, but it's addressing a genuine unmet need."

4. Connect to a broader theme: "It also highlights the role of regulatory agencies like the MHRA in conducting primary research, not just evaluating applications—something I hadn't fully appreciated before reading about this."

Why this works

You've demonstrated:

• Accuracy: You understand the translational pipeline and aren't conflating lab findings with clinical readiness.
• Judgement: You can assess the significance of research without hype.
• Curiosity: You've reflected on what the story reveals about the research ecosystem, not just the headline.
• Communication: You've signposted your answer so the interviewer can follow your reasoning.

The wider principle

When discussing anything described as a "breakthrough," "first," or "novel," ask yourself:

• What stage is this? (Lab, animal, phase I/II/III trial, approved, in use?)
• For whom does this matter, and when? (Patients now, researchers now, patients eventually?)
• What would need to happen next?

If you can't answer those questions, the story probably isn't interview-ready yet. But if you can, you've got material that sets you apart.

For more on structuring answers around innovation and research, explore Interview Preparation and Structuring Answers Under Pressure.

World Diabetes Day is this Friday. Whether or not you're interviewed this month, awareness days are low-hanging fruit for interview preparation—if you use them strategically.

Tip 1: Track the next three

Pick three awareness days falling between now and February (peak interview season). For each, spend 20 minutes reading the WHO or NHS campaign page. Note:

• The theme for 2026 (it changes yearly)
• One statistic that surprised you
• One policy or service gap it highlights

You now have three stories that demonstrate breadth (you're reading beyond course requirements) and currency (you're engaging with live public-health priorities).

Tip 2: Go one layer deeper than the hashtag

Awareness days generate social media noise. Most of it is surface-level. Your job is to read the source material—the WHO campaign toolkit, the NHS England policy statement, the charity's annual report. This is where you find the why: why this year's theme was chosen, what evidence drove it, what the campaign is trying to change.

For World Diabetes Day, the surface story is "know the symptoms." The deeper story is "40% undiagnosed, with a 2030 target of 80% diagnosis"—which reveals a system-level challenge, not just individual knowledge gaps.

Tip 3: Connect it to something you've seen

If you've had work experience in GP, pharmacy, or community settings, you've probably encountered the condition the awareness day addresses. Reflect:

• Did I see screening happening? If not, why not?
• What barriers might patients face in accessing diagnosis or treatment?
• How did the clinical team talk about prevention?

This turns a general topic into a personal observation, which makes for much stronger interview material.

This week's action: Spend 15 minutes on the WHO World Diabetes Day 2026 page. Read the six action points for health workers. Pick one and think: How would I explain why this matters to a patient, or to a policymaker? That's your interview answer.

For a full curriculum of topics to cover before interviews, see The Interview Reading Path.

Liverpool's five-year MBChB (A100) is built around a spiral curriculum organised into five suprathemes: Science and Scholarship, Core Skills, The Good Doctor, Patient in the Community Setting, and Patient in Secondary Care. Concepts are introduced and revisited at increasing complexity across all five years.

Course structure

Years 1–2: Campus-based teaching covering core clinical science (Year 1: normal structure and function; Year 2: pathology, disease, and environmental interactions). Year 1 is entirely on the Liverpool campus; from Year 2 onwards, you rotate through clinical placements in NHS Trusts, GP practices, hospices, and specialist services.

Years 3–5: Core clinical practice (Year 3), specialist and challenging clinical practice (Year 4), and emergency and acute medicine (Year 5). All three years are placement-heavy, with students gaining real-world experience across diverse settings.

Liverpool also offers a four-year graduate-entry route (A101), which compresses Years 1 and 2 into a single intensive year starting in early August. GEP students join the standard programme's clinical rotations from Year 2 (equivalent to Year 3 of A100). Note: A101 is UK applicants only, accepts no deferrals, and requires GAMSAT (not UCAT).

Entry requirements (A100)

A-levels: AAA to include Chemistry and one of Biology, Physics, or Maths, plus a third academic subject. Alternatively, A*AB with the A* and A in Chemistry and one science/maths, and B in the third subject. Science practicals must be passed where applicable.

GCSEs: Minimum nine GCSEs by end of Year 11, including English Language, Maths, Biology, and Chemistry (or dual/combined science) at grade B/6 minimum. Liverpool uses a points system: A*/A/7/8/9 = 2 points; B/6 = 1 point. You need a minimum of 15 points from your best nine GCSEs. Physics is not required.

UCAT: Required for non-graduate A100 applicants. Liverpool uses a two-stage threshold system: both GCSE points and UCAT score must meet minimum cut-offs before interview invitations are issued. For 2024 entry, the UCAT threshold was approximately 2580/3600 (scaled score ≈1910 for home applicants). Thresholds vary yearly depending on applicant cohort strength.

Selection process

Liverpool operates two cut-offs (GCSE + UCAT), both of which must be met. Beyond the thresholds, preference may be given to higher GCSE scores in borderline cases. Interviews are MMI format (Multiple Mini Interviews), typically held December–February, testing communication, ethical reasoning, motivation, and global-health awareness. Decisions are released from March onwards.

No offers are made without interview. Non-academic attributes are assessed at interview only, not on paper.

What makes Liverpool distinctive?

Global opportunities: Liverpool offers an optional Year in China programme for selected students, providing international clinical and cultural experience.

TEF Gold: The University holds a Gold award in the Teaching Excellence Framework (2023), valid for four years, recognising high-quality teaching and student outcomes.

Curriculum philosophy: The spiral model ensures that foundational knowledge is reinforced and deepened across all five years, rather than frontloaded and forgotten. The five suprathemes integrate vertical strands (e.g., professionalism, ethics, research, prescribing) throughout, so you're never learning in silos.

Key dates for 2027 entry

• UCAS deadline: 15 October 2026, 6pm (medicine applications)
• Course starts: 28 September 2027
• UCAT: Must be completed by the appropriate closing date (typically late September/early October 2026)
• Interview period: December 2026–February 2027

Application codes

• A100 (standard entry): Institution code L41
• A101 (graduate entry): Institution code L41

Strategic considerations

Liverpool's dual-threshold system (GCSE + UCAT) is unusual and means that a very strong UCAT alone won't compensate for weaker GCSEs, and vice versa. If your GCSE profile is below 15 points or your UCAT is predicted below ≈1900 (home tier), Liverpool may be a higher-risk choice. Conversely, if both metrics are comfortably above threshold, Liverpool's MMI format rewards strong communicators and reflective thinkers, making it a good fit for applicants with robust work experience and structured answers.

For more on Liverpool's entry requirements, UCAT strategy, and how to structure your UCAS application, see UCAT Preparation, Application Strategy, and TrueScore UCAT Predictions.

NextGenMedPrep TrueScore for University of Liverpool: ~1900/2700 — the UCAT score we predict you'll need to reach interview (2027 entry). See all predictions and check our Medical School Rankings.